Purpose: To investigate and study the relationship between the PLCE1 rs2274223 gene polymorphism andsusceptibility to esophageal cancer by meta-analysis. Materials and
Methods: The literature was searched inWanfang, CNKI, PubMed, CBM, Web of Science, MEDLINE, EMBASE, Springer, Elsevier and Cochranedatabases from the date of January 1st 2004 to April 1st 2014 to collect case-control studies on the PLCE1polymorphism and susceptibility to esophageal cancer. For the population genotype distributions of bothesophagus cancer and control groups, their odds ratios (ORs) and 95% confidence intervals (CIs) were takenas effect indexes. Disqualified studies were excluded. Odds ratios of PLCE1 rs2274223 genotype distributionsin the group of patients with esophageal cancer and the group of healthy control were calculated. The metaanalysissoftware, RevMan5.0, was applied for heterogeneity test, pooled OR and 95% confidence intervals.Sensitivity analysis and publication bias were also explored.
Results: A total of twelve case-control studies wereincluded, covering a total of 9, 912 esophageal cancer cases and 13, 023 controls were included. The pooledodds ratio of PLCE1 rs2274223 genotype GA vs AA was 1.29 (95%CI=1.17~1.43), p<0.01, GG vs AA was 1.65(95%CI=1.32~2.05), p<0.01, GG/GA vs AA was 1.30 (95%CI=1.16~1.46), p<0.01 and GG vs GA/AA was 1.48(95%CI=1.22~1.80), p<0.01. The PLCE1 rs2274223 polymorphism was thus associated with risk of esophagealcancer in all genetic models. In the stratified analysis by ethnicity, and source of controls, no significantlyincreased risk was observed for white persons. There was no obvious publication bias detected.
Conclusions:This meta-analysis showed there was a significantly association between PLCE1 rs2274223 polymorphism andesophageal cancer in yellow race populations. Due to some minor limitations, our findings should be confirmedin further studies.